A Phase 1/2 interventional study of JCAR017 and Lymphodepleting in Precursor Cell Lymphoblastic Leukemia-Lymphoma and Lymphoma, Non-Hodgkin, sponsored by Celgene. Terminated at 19 sites in 6 countries. Open to participants aged Up to 25 Years. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Bristol-Myers Squibb.
Among the 12 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Bristol-Myers Squibb, this one is the only one that started in 2018, is one of 3 in phase 1/2, and was the 11th registered.
2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →None of the 12 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Bristol-Myers Squibb is open now. The open studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, anywhere →
Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.
This study: Up to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 3
First in 2003; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 82 across the 9 interventional studies, 11 across the 2 observational. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2, open-label, single arm, multicohort study to evaluate the safety and efficacy of JCAR017 in pediatric subjects aged ≤ 25 years with CD19+ r/r B-ALL and B-NHL.
Phase 1 will identify a recommended Phase 2 dose (RP2D). Phase 2 will evaluate the efficacy of JCAR017 RP2D in the following three disease cohorts: Cohort 1 (r/r B-ALL), Cohort 2 (MRD+ B-ALL) and Cohort 3 (r/r B-NHL, [DLBCL, BL, or PMBCL]). A Simon's Optimal two-stage study design will be applied to Cohort 1 and 2 in Phase 2.
This is a Phase 1/2, open-label, single arm, multicohort study incorporating Simon's Optimal two-stage design to evaluate the safety and efficacy of JCAR017 in pediatric subjects aged ≤ 25 years with CD19+ r/r B-ALL and B-NHL.
In the Phase 1, up to 5 dose levels will be of JCAR017 will be evaluated. Enrollment will commence in pediatric subjects with r/r B-ALL at Dose Level 1 (DL1) of 0.05x10\^6 CAR+ T cells/kg (maximum DL1 of 5x10\^6 JCAR017 CAR+ T cells [non-weight adjusted]). If this dose is confirmed to be safe and tolerable, additional subjects will be enrolled at higher dose(s) up to 0.75 x10\^6 CAR+ T cells/kg (maximum of 75x10\^6 JCAR017 CAR+ T cells [non-weight adjusted]) with the aim to identify the RP2D. Dose escalation/de-escalation will follow a modified toxicity probability interval (mTPI-2) algorithm. A Safety Review Committee (SRC) will recommend the Phase 2 dose (defined as RP2D) based on an integrated assessment of the safety, PK and preliminary efficacy information from at least 10 pediatric subjects treated at the RP2D.
In Phase 2, a minimum of 71 additional subjects (\< 18 years of age) will be enrolled into one of the 3 cohorts listed below. The sample size for Cohorts 1 and 2 is calculated according to Simon's Optimal two-stage design. The 10 or more pediatric subjects treated at the RP2D in Phase 1 will form part of the sample size (ie, Cohort 1 and Cohort 2). Therefore, the protocol intends to treat 81 primary endpoint evaluable pediatric subjects in Phase 2, if warranted by the evaluation of results at the completion of the first stage of the study in each cohort.
Up to 20 additional B-ALL subjects between 18 and 25 years of age may be enrolled in Phase 2.
Following treatment with JCAR017 subjects will then enter the post-treatment period for disease progression/relapse, safety, CAR T cell persistence, and survival up to 24 months after administration of JCAR017.
Efficacy will be assessed both locally and by an Independent Review Committee. Response assessments will be based on bone marrow and blood morphologic criteria, physical examination findings, along with laboratory assessments of cerebral spinal fluid (CSF) and bone marrow MRD (B-ALL only) assessments. B-NHL subjects will also have radiographic disease assessment by CT/MRI scans and tumor biopsies, if accessible.
Post-study follow-up for survival, relapse, long-term toxicity, and lentiviral vector safety will continue under a separate long-term follow-up protocol for up to 15 years after the JCAR017 infusion as per health authority regulatory guidelines.
An Independent Data Monitoring Committee will monitor the study conduct.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must satisfy the following criteria to be enrolled in the study:
Phase 1: Subject \< 18 years of age and weighs ≥ 6 kg at the time of signing the form (ICF)/informed assent form (IAF).
Phase 2: Subject ≤ 25 years of age and weighs ≥ 6 kg at the time of signing the ICF/IAF.
Diagnosis of B-cell ALL or B-cell NHL as defined below:
Phase 1: Subjects with r/r B-ALL, defined as morphological evidence of disease in BM (5% or greater lymphoblast by morphology) and either of the following:
Phase 2: Subjects with one of the following:
Cohort 1: r/r B-ALL, defined as morphological evidence of disease in BM (5% or greater lymphoblast by morphology) and either:
Cohort 2: MRD+ B-ALL, defined as:
Note: B-NHL subjects with secondary CNS lymphoma involvement are eligible however subject selection must consider clinical risk factors for severe neurological AEs and alternative treatment options. Subjects should only be enrolled if the Investigator considers the potential benefit outweighs the risk for the subject.
Adequate organ function, defined as:
Serum creatinine based on age/gender as described below. Subjects that do not meet the criteria but who have a or radioisotope (GFR) > 70 mL/min/1.73 m2 are eligible.• (ALT) ≤ 5 x (ULN) and total \< 2.0 mg/dL (or \< 3.0 mg/dL for subjects with Gilbert's syndrome or leukemic/lymphomatous infiltration of the liver).
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
Subject has used the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JCAR017 cells infusion. Phase 1 will evaluate up to 5 JCAR017 cells dose levels and dose escalation/de-escalation will follow a modified toxicity probability interval (mTPI-2) algorithm. The declared RP2D in Phase 1 will be applied to the subjects enrolled in Phase 2
Drug: JCAR017 · Drug: Lymphodepleting · Drug: Fludarabine · Drug: Cyclophosphamide
JCAR017
Lymphodepleting
Fludarabine
Cyclophosphamide
Number of Participants With Treatment Emergent Adverse Events up to 30 Days Post JCAR017 Infusion
An AE is defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. Treatment Emergent Adverse Events (TEAEs) are defined as any AE occurring or worsening on the day of the JCAR017 infusion until 30 days post-treatment (JCAR017 infusion) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or greater.
Time frame: From first JCAR017 infusion (Day 1) to 30 days after JCAR017 infusion
Number of Participants With Dose Limiting Toxicities
A DLT was defined as: * Death not related to disease progression * Grade (Gr) 4 (Life-threatening) neurotoxicity * Gr 3 (Severe) neurotoxicity of greater than 7 days * Gr 3 neurotoxicity does not revert to baseline within 28 days of the start date of the Grade 3 event * Seizures of grade that do not resolve within 7 days * Gr 4 cytokine release syndrome (CRS) that does not resolve to Grade ≤ 3 within 3 days * Gr 3 CRS that does not resolve to Grade ≤ 2 within 7 days * Any increase in aspartate aminotransferase (AST) or ALT \> 3 × ULN and concurrent increase in total bilirubin \> 2 × ULN that is unrelated to CRS and has no other probable reason to explain the combination of increases * Any cardiac, dermatologic, gastrointestinal, hepatic, pulmonary, renal/genitourinary, or neurologic Gr 3 or 4 event not pre-existing or not due to the underlying malignancy * Any other Gr 3 or 4 event deemed unexpected by the Investigator and considered a DLT upon evaluation by the safety review committee
Time frame: From first JCAR017 infusion (Day 1) to 28 days after JCAR017 infusion
Concentration of JCAR017 in Peripheral Blood at Day 28 Post JCAR017 Infusion
Concentration of JCAR017 in Peripheral Blood was assessed by droplet digital polymerase chain reaction.
Time frame: At day 28 post JCAR017 infusion
Number of Participants With Treatment-Emergent Adverse Events up to 90 Days Post JCAR017 Infusion
An AE is defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. Treatment Emergent Adverse Events (TEAEs) are defined as any AE occurring or worsening on the day of the JCAR017 infusion until 90 days post-treatment (JCAR017 infusion) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or greater. The following scale for grading was used - Grade 3 = Severe, Grade 4 = Life-Threatening.
Time frame: From first JCAR017 infusion (Day 1) to 90 days after JCAR017 infusion
Number of Participants With Serious Treatment-Emergent Adverse Events up to 90 Days Post JCAR017 Infusion
Serious adverse events (SAE) are defined as any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/ birth defect; constitutes an important medical event. Treatment Emergent Adverse Events (TEAEs) are defined as any AE occurring or worsening on the day of the JCAR017 infusion until 90 days post-treatment (JCAR017 infusion) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or greater.
Time frame: From first JCAR017 infusion (Day 1) to 90 days after JCAR017 infusion
Change From Baseline at Day 28 in Hematology Laboratory Parameters- Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
Time frame: Baseline and at Day 28
Change From Baseline at Day 28 in Hematology Laboratory Parameters- Basophils/Leukocytes; Eosinophils/Leukocytes; Lymphocytes/Leukocytes; Neutrophils/Leukocytes; Monocytes/Leukocytes
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
Time frame: Baseline and at Day 28
Change From Baseline at Day 28 in Hematology Laboratory Parameters- Erythrocytes
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
Time frame: Baseline and at Day 28
Change From Baseline at Day 28 in Hematology Laboratory Parameters- Hematocrit
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
Time frame: Baseline and at Day 28
Change From Baseline at Day 28 in Hematology Laboratory Parameters- Hemoglobin
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
Time frame: Baseline and at Day 28
Change From Baseline at Day 28 in Chemistry Laboratory Parameters- Alanine Aminotransferase; Alkaline Phosphatase; Aspartate Aminotransferase; Lactate Dehydrogenase
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
Time frame: Baseline and at Day 28
Change From Baseline at Day 28 in Laboratory Parameters- Albumin; Protein
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
Time frame: Baseline and at Day 28
Change From Baseline at Day 28 in Chemistry Laboratory Parameters- Bicarbonate; Blood Urea Nitrogen; Calcium; Chloride; Glucose; Magnesium; Phosphate; Potassium; Sodium, Triglyceride
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
Time frame: Baseline and at Day 28
Change From Baseline at Day 28 in Chemistry Laboratory Parameters- Bilirubin; Creatinine; Direct Bilirubin; Urate
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
Time frame: Baseline and at Day 28
Number of Participants With Manufacturing Success of JCAR017 Product
Successful product was defined as JCAR017 product was generated and able to be QC released (including nonconforming product) for infusion. Unsuccessful product is defined as no JCAR017 product could be generated after two manufacturing attempts using a single apheresis product for starting material or product was unable to be QC released for infusion.
Time frame: From screening to JCAR017 infusion (day -35 to day 1)
Overall Response Rate (ORR)
ORR is defined as the percentage of participants who achieved either a complete response (CR) or complete response with incomplete blood recovery (CRi) on Day 28 that is confirmed on Day 56. Response assessment was performed according to the 2019 Comprehensive Cancer Network (NCCN) response criteria guidelines for pediatric acute lymphoblastic leukemia (ALL). CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL.
Time frame: Up to Day 56
Duration of Response (DOR)
DOR is defined as time from first response (either CR or CRi) until progressive disease (PD), disease relapse, or death from any cause, whichever occurs first. Response assessment was performed according to the 2019 Comprehensive Cancer Network (NCCN) response criteria guidelines for pediatric ALL. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.
Time frame: From first response (either CR or CRi) until progressive disease (PD), disease relapse, or death from any cause, whichever occurs first (Up to approximately 14 months)
Relapse Free Survival (RFS)
RFS is defined as time from conforming JCAR017 infusion to the first progressive disease (PD), relapsed disease or death from any cause, whichever occurs first. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. Relapsed disease is defined as Reappearance of blasts in the blood or bone marrow (\> 5%) or \> 1% with previous/supportive molecular findings or in any extramedullary site after a CR. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks.
Time frame: Up to approximately 15 months
Event Free Survival (EFS)
EFS is defined as time from conforming JCAR017 infusion to progressive disease (PD), relapsed disease, start of a new anticancer therapy including HSCT or death from any cause, whichever occurs first. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. Relapsed disease is defined as Reappearance of blasts in the blood or bone marrow (\> 5%) or \> 1% with previous/supportive molecular findings or in any extramedullary site after a CR. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. Only responders are included in he analysis. Censored participants were also analyzed.
Time frame: From conforming JCAR017 infusion to PD, relapsed disease, start of a new anticancer therapy including Hematopoietic Stem Cell Transplant (HSCT) or death from any cause, whichever occurs first (Up to approximately 15 months)
Overall Survival (OS)
OS is defined as the interval from the date of first confirming JCAR017 infusion to the date of death due to any reason.
Time frame: From the date of first confirming JCAR017 infusion to the date of death due to any reason (Up to approximately 24 months)
Minimal Residual Response (MRD) Negative Response Rate
Minimal Residual Disease (MRD) Negative Response Rate is defined as the percentage of participants achieving either a CR or CRi with a MRD negative bone marrow on Day 28, confirmed on Day 56. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. Disease assessments recorded on or after start of a new anticancer therapy, including HSCT, will not be considered, nor will disease assessments reported after a PD or relapse has been observed.
Time frame: Up to Day 56
Number of Participants Who Achieved a Response After JCAR017 Infusion and Then Proceeded to Hematopoietic Stem Cell Transplant
Number of participants who undergo HSCT after receiving a JCAR017 infusion and achieving a response are presented. The time of proceeding to HSCT is defined as the time of commencing the conditioning regimen as required for HSCT. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.
Time frame: Up to approximately 24 months
| Milestone | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg | Not Assigned |
|---|---|---|---|---|
| Started | 9 | 8 | 3 | 1 |
| Completed | 8 | 7 | 1 | 0 |
| Not completed | 1 | 1 | 2 | 1 |
| Withdrew: Failure to meet treatment criteria | 0 | 0 | 2 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 1 |
| Withdrew: Study drug manufacturing failure | 1 | 0 | 0 | 0 |
| Milestone | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg | Not Assigned |
|---|---|---|---|---|
| Started | 8 | 7 | 1 | 0 |
| Completed | 7 | 7 | 1 | 0 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 0 | 0 | 0 |
| Milestone | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg | Not Assigned |
|---|---|---|---|---|
| Started | 7 | 7 | 1 | 0 |
| Completed | 3 | 6 | 1 | 0 |
| Not completed | 4 | 1 | 0 | 0 |
| Withdrew: Other reason | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 0 | 0 | 0 |
An AE is defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. Treatment Emergent Adverse Events (TEAEs) are defined as any AE occurring or worsening on the day of the JCAR017 infusion until 30 days post-treatment (JCAR017 infusion) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or greater.
| Participants | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events up to 30 Days Post JCAR017 Infusion | 7 | 6 | 1 |
A DLT was defined as: * Death not related to disease progression * Grade (Gr) 4 (Life-threatening) neurotoxicity * Gr 3 (Severe) neurotoxicity of greater than 7 days * Gr 3 neurotoxicity does not revert to baseline within 28 days of the start date of the Grade 3 event * Seizures of grade that do not resolve within 7 days * Gr 4 cytokine release syndrome (CRS) that does not resolve to Grade ≤ 3 within 3 days * Gr 3 CRS that does not resolve to Grade ≤ 2 within 7 days * Any increase in aspartate aminotransferase (AST) or ALT \> 3 × ULN and concurrent increase in total bilirubin \> 2 × ULN that is unrelated to CRS and has no other probable reason to explain the combination of increases * Any cardiac, dermatologic, gastrointestinal, hepatic, pulmonary, renal/genitourinary, or neurologic Gr 3 or 4 event not pre-existing or not due to the underlying malignancy * Any other Gr 3 or 4 event deemed unexpected by the Investigator and considered a DLT upon evaluation by the safety review committee
| Participants | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities | 0 | 2 | 1 |
Concentration of JCAR017 in Peripheral Blood was assessed by droplet digital polymerase chain reaction.
| copies per microgram | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Concentration of JCAR017 in Peripheral Blood at Day 28 Post JCAR017 Infusion | 1131.821 ± 64.658 | 1457.591 ± 75.558 | 2847.910 ± NA |
An AE is defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. Treatment Emergent Adverse Events (TEAEs) are defined as any AE occurring or worsening on the day of the JCAR017 infusion until 90 days post-treatment (JCAR017 infusion) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or greater. The following scale for grading was used - Grade 3 = Severe, Grade 4 = Life-Threatening.
| Participants | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| At least one TEAE | 7 | 6 | 1 |
| At least one grade 3/4 TEAE | 6 | 5 | 1 |
| At Least One TEAE Related To JCAR017 | 5 | 5 | 1 |
| At Least One grade 3/4 TEAE Related To JCAR017 | 3 | 4 | 1 |
Serious adverse events (SAE) are defined as any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/ birth defect; constitutes an important medical event. Treatment Emergent Adverse Events (TEAEs) are defined as any AE occurring or worsening on the day of the JCAR017 infusion until 90 days post-treatment (JCAR017 infusion) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or greater.
| Participants | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| AT Least one Serious TEAE | 5 | 3 | 1 |
| At Least One Serious TEAE Related To JCAR017 | 1 | 3 | 1 |
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
| 10^9 cells/L | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Basophils | 0.00 ± 0.025 | -0.01 ± 0.023 | -0.01 ± NA |
| Eosinophils | 0.03 ± 0.048 | 0.08 ± 0.114 | -0.08 ± NA |
| Leukocytes | 4.01 ± 8.338 | 0.59 ± 1.753 | -2.00 ± NA |
| Lymphocytes | -0.22 ± 0.879 | 0.27 ± 1.286 | -0.57 ± NA |
| Monocytes | 0.11 ± 0.163 | 0.09 ± 0.173 | -0.22 ± NA |
| Neutrophils | 0.41 ± 0.782 | -0.18 ± 0.735 | -1.50 ± NA |
| Platelets | 27.33 ± 132.672 | -68.60 ± 168.583 | -163.00 ± NA |
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
| Ratio | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Basophils/Leukocytes | 0.25 ± 0.885 | -0.24 ± 0.654 | -0.30 ± NA |
| Eosinophils/Leukocytes | 0.85 ± 1.402 | 4.28 ± 5.389 | -2.90 ± NA |
| Lymphocytes/Leukocytes | -29.57 ± 21.690 | -16.30 ± 25.140 | 33.80 ± NA |
| Neutrophils/Leukocytes | 26.45 ± 26.815 | 10.70 ± 18.797 | -33.90 ± NA |
| Monocytes/Leukocytes | 4.35 ± 10.123 | 1.74 ± 4.515 | 0.20 ± NA |
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
| 10^12 cells/L | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Change From Baseline at Day 28 in Hematology Laboratory Parameters- Erythrocytes | 0.04 ± 0.781 | 0.08 ± 0.268 | -0.70 ± NA |
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
| proportion of red blood cells in blood | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Change From Baseline at Day 28 in Hematology Laboratory Parameters- Hematocrit | 0.00 ± 0.068 | 0.02 ± 0.016 | -0.03 ± NA |
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
| grams per liter | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Change From Baseline at Day 28 in Hematology Laboratory Parameters- Hemoglobin | 2.33 ± 24.312 | 6.20 ± 6.834 | -13.00 ± NA |
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
| units per liter | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Alanine aminotransferase | 5.33 ± 19.439 | 4.50 ± 16.299 | -19.00 ± NA |
| Alkaline phosphatase | 53.50 ± 158.322 | 78.75 ± 40.950 | -121.00 ± NA |
| Aspartate aminotransferase | 29.17 ± 72.204 | 11.50 ± 13.675 | -1.00 ± NA |
| Lactate dehydrogenase | 992.33 ± 2238.888 | 22.25 ± 43.684 | -36.00 ± NA |
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
| grams per liter | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Albumin | 5.83 ± 9.663 | 6.75 ± 2.062 | -3.00 ± NA |
| Protein | 4.00 ± 12.602 | 5.00 ± 6.683 | -6.00 ± NA |
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
| mmol/L | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Bicarbonate | 2.53 ± 4.453 | -2.65 ± 1.919 | 4.10 ± NA |
| Blood Urea Nitrogen | 3.60 ± 3.542 | 2.43 ± 0.826 | 0.20 ± NA |
| Calcium | 0.13 ± 0.157 | 0.04 ± 0.058 | -0.17 ± NA |
| Chloride | -1.50 ± 4.324 | 1.50 ± 1.291 | 1.00 ± NA |
| Glucose | 0.32 ± 0.641 | -0.08 ± 0.472 | 14.90 ± NA |
| Magnesium | 0.06 ± 0.107 | 0.06 ± 0.109 | 0.00 ± NA |
| Phosphate | 0.02 ± 0.281 | -0.02 ± 0.336 | -0.16 ± NA |
| Potassium | -0.05 ± 0.672 | 0.20 ± 0.535 | 1.50 ± NA |
| Sodium | 1.00 ± 2.608 | 2.25 ± 2.217 | 2.00 ± NA |
| Triglyceride | 0.45 ± 1.652 | 0.29 ± 0.320 | 0.33 ± NA |
Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.
| umol/L | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Bilirubin | 20.26 ± 41.498 | -1.00 ± 6.928 | 2.00 ± NA |
| Creatinine | 9.84 ± 14.218 | 1.50 ± 9.000 | -2.00 ± NA |
| Direct Bilirubin | 13.44 ± 33.601 | -0.25 ± 0.500 | 0.00 ± NA |
| Urate | 43.51 ± 94.081 | 85.00 ± 71.615 | 9.00 ± NA |
Successful product was defined as JCAR017 product was generated and able to be QC released (including nonconforming product) for infusion. Unsuccessful product is defined as no JCAR017 product could be generated after two manufacturing attempts using a single apheresis product for starting material or product was unable to be QC released for infusion.
| Participants | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg | Not Assigned |
|---|---|---|---|---|
| Number of Participants With Manufacturing Success of JCAR017 Product | 7 | 7 | 2 | 1 |
ORR is defined as the percentage of participants who achieved either a complete response (CR) or complete response with incomplete blood recovery (CRi) on Day 28 that is confirmed on Day 56. Response assessment was performed according to the 2019 Comprehensive Cancer Network (NCCN) response criteria guidelines for pediatric acute lymphoblastic leukemia (ALL). CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL.
| percentage of participants | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Overall Response Rate (ORR) | 50.0 (11.8 to 88.2) | 25.0 (0.6 to 80.6) | 100.0 (2.5 to 100.0) |
DOR is defined as time from first response (either CR or CRi) until progressive disease (PD), disease relapse, or death from any cause, whichever occurs first. Response assessment was performed according to the 2019 Comprehensive Cancer Network (NCCN) response criteria guidelines for pediatric ALL. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.
| months | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Duration of Response (DOR) | 13.70 (2.46 to 13.70) | NA (4.93 to 4.93) | NA (2.23 to 2.23) |
RFS is defined as time from conforming JCAR017 infusion to the first progressive disease (PD), relapsed disease or death from any cause, whichever occurs first. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. Relapsed disease is defined as Reappearance of blasts in the blood or bone marrow (\> 5%) or \> 1% with previous/supportive molecular findings or in any extramedullary site after a CR. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks.
| months | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Relapse Free Survival (RFS) | 7.77 (0.46 to 14.62) | 6.98 (1.15 to 8.97) | NA (3.12 to 3.12) |
EFS is defined as time from conforming JCAR017 infusion to progressive disease (PD), relapsed disease, start of a new anticancer therapy including HSCT or death from any cause, whichever occurs first. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. Relapsed disease is defined as Reappearance of blasts in the blood or bone marrow (\> 5%) or \> 1% with previous/supportive molecular findings or in any extramedullary site after a CR. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. Only responders are included in he analysis. Censored participants were also analyzed.
| months | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Event Free Survival (EFS) | 3.24 (0.46 to 14.62) | 5.42 (1.15 to 8.97) | 3.12 (3.12 to 3.12) |
OS is defined as the interval from the date of first confirming JCAR017 infusion to the date of death due to any reason.
| months | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Overall Survival (OS) | 7.13 (0.76 to NA) | 7.08 (4.99 to NA) | 8.90 (NA to NA) |
Minimal Residual Disease (MRD) Negative Response Rate is defined as the percentage of participants achieving either a CR or CRi with a MRD negative bone marrow on Day 28, confirmed on Day 56. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. Disease assessments recorded on or after start of a new anticancer therapy, including HSCT, will not be considered, nor will disease assessments reported after a PD or relapse has been observed.
| percentage of participants | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Minimal Residual Response (MRD) Negative Response Rate | 16.7 (0.4 to 64.1) | 25.0 (0.6 to 80.6) | 100.0 (2.5 to 100.0) |
Number of participants who undergo HSCT after receiving a JCAR017 infusion and achieving a response are presented. The time of proceeding to HSCT is defined as the time of commencing the conditioning regimen as required for HSCT. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.
| Participants | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg |
|---|---|---|---|
| Number of Participants Who Achieved a Response After JCAR017 Infusion and Then Proceeded to Hematopoietic Stem Cell Transplant | 1 | 1 | 1 |
Collected over All-cause mortality was collected from JCAR017 infusion until their study completion (up to approximately 1928 days). Serious and non-serious adverse events were collected from first JCAR017 infusion (Day 1) to 90 days post JCAR017 infusion.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.05 x 10^6 CAR+ T Cells/kg | 6/9 (66.7%) | 5/7 (71.4%) | 7/7 (100%) |
| 0.15 x 10^6 CAR+ T Cells/kg | 4/8 (50%) | 3/6 (50%) | 6/6 (100%) |
| 0.50 x 106 CAR+T Cells/kg | 1/3 (33.3%) | 1/1 (100%) | 1/1 (100%) |
| Not Assigned | 1/1 (100%) | — | — |
| Event | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg | Not Assigned |
|---|---|---|---|---|
| Brain oedemaNervous system disorders | 0/7 | 0/6 | 1/1 | — |
| NeurotoxicityNervous system disorders | 1/7 | 1/6 | 1/1 | — |
| Cytokine release syndromeImmune system disorders | 0/7 | 3/6 | 0/1 | — |
| Infusion related reactionInjury, poisoning and procedural complications | 0/7 | 1/6 | 0/1 | — |
| PneumoniaInfections and infestations | 1/7 | 0/6 | 0/1 | — |
| SepsisInfections and infestations | 1/7 | 0/6 | 0/1 | — |
| ViraemiaInfections and infestations | 1/7 | 0/6 | 0/1 | — |
| Extradural haematomaInjury, poisoning and procedural complications | 1/7 | 0/6 | 0/1 | — |
| Event | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg | Not Assigned |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 5/7 | 5/6 | 1/1 | — |
| CoagulopathyBlood and lymphatic system disorders | 0/7 | 0/6 | 1/1 | — |
| LeukopeniaBlood and lymphatic system disorders | 4/7 | 1/6 | 1/1 | — |
| NeutropeniaBlood and lymphatic system disorders | 3/7 | 2/6 | 1/1 | — |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/7 | 3/6 | 1/1 | — |
| BradycardiaCardiac disorders | 0/7 | 1/6 | 1/1 | — |
| TachycardiaCardiac disorders | 0/7 | 0/6 | 1/1 | — |
| DiarrhoeaGastrointestinal disorders | 0/7 | 1/6 | 1/1 | — |
| Cytokine release syndromeImmune system disorders | 4/7 | 1/6 | 1/1 | — |
| HypogammaglobulinaemiaImmune system disorders | 1/7 | 1/6 | 1/1 | — |
| Age, Customized(participants) | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg | Not Assigned | Total |
|---|---|---|---|---|---|
| < 6 years | 3 | 4 | 2 | 0 | 9 |
| >= 6 to < 12 years | 5 | 3 | 1 | 0 | 9 |
| >= 12 to < 18 years | 1 | 1 | 0 | 1 | 3 |
| Sex: Female, Male(Participants) | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg | Not Assigned | Total |
|---|---|---|---|---|---|
| Female | 5 | 4 | 2 | 0 | 11 |
| Male | 4 | 4 | 1 | 1 | 10 |
| Ethnicity (NIH/OMB)(Participants) | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg | Not Assigned | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 1 | 1 | 9 |
| Not Hispanic or Latino | 4 | 4 | 2 | 0 | 10 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | 0.05 x 10^6 CAR+ T Cells/kg | 0.15 x 10^6 CAR+ T Cells/kg | 0.50 x 106 CAR+T Cells/kg | Not Assigned | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 1 | 3 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 6 | 5 | 3 | 0 | 14 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 0 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Jan 2024, 63 months.
Results were first posted in Aug 2024, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisocabtagene maraleucel
Precursor Cell Lymphoblastic Leukemia-Lymphoma →